In vitro transcribed (IVT) mRNA drugs: technical progress and application prospect / 药学学报
Acta Pharmaceutica Sinica
; (12): 2047-2058, 2023.
Article
en Zh
| WPRIM
| ID: wpr-999118
Biblioteca responsable:
WPRO
ABSTRACT
The in vitro transcribed (IVT) mRNA technology has progressed rapidly and the application of mRNA vaccines in the COVID-19 pandemic made it become the most talked-about topic. Compared with protein drugs, IVT mRNA has a lower cost; it can be modular produced and its sequence can be modified easily, so it has a broad application prospect. However, due to its short history, mRNA drugs face the problem of lacking sufficient clinical data, and there is no quality control standard for mRNA drugs except mRNA vaccines. We overview the sequence design, delivery vectors, administration, application prospect and safety considerations of mRNA drugs. We also discussed the quality control of mRNA drugs briefly.
Texto completo:
1
Base de datos:
WPRIM
Idioma:
Zh
Revista:
Acta Pharmaceutica Sinica
Año:
2023
Tipo del documento:
Article